Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.
Часто задаваемые вопросы
В каком секторе работает Zynerba Pharmaceuticals, Inc (ZYNE-RM)?
Zynerba Pharmaceuticals, Inc относится к сектору Здравоохранение.
Выплачивает ли Zynerba Pharmaceuticals, Inc (ZYNE-RM) дивиденды?
Нет, Zynerba Pharmaceuticals, Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Zynerba Pharmaceuticals, Inc (ZYNE-RM)?
У компании Zynerba Pharmaceuticals, Inc бета 0.390, что указывает на более низкую волатильность по сравнению с рынком в целом.
